Changes in Bone Density during Development - Osteogenesis Imperfecta - page 211

osteoporosis in children and adolescents: the ISCD 2007
Pediatric Oficial Positions. J Clin Densitom 2008;11:22-8.
[9] Gordon CM, Bachrach LK, Carpenter TO, Crabtree N, El-Hajj
Fuleihan G, Kutilek S, et al. Dual energy X-ray absorptiometry
interpretation and reporting in children and adolescents: the 2007
ISCD Pediatric Oficial Positions. J Clin Densitom 2008;11:43-58.

children with osteogenesis imperfecta with emphasis on the inter-
pretation of bone mineral density for local standards. J Pediatr
Orthop 2008;28:483-7.

[26] Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J. Osteogenesis

imperfecta: anthropometric, skeletal and mineral metabolic effects
of long-term intravenous pamidronate therapy. Acta Paediatr
2006;95:332-9. [10] Carter DR, Bouxsein ML, Marcus R. New approaches for inter-

preting projected bone densitometry data. J Bone Miner Res
1992;7:137-45.

[27] Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous

pamidronate treatment in children with moderate to severe
osteogenesis imperfecta: assessment of indices of dual-energy
X-ray absorptiometry and bone metabolic markers during the
irst year of therapy. Bone 2004;34:539-46.

[11] Kroger H, Vainio P, Nieminen J, Kotaniemi A. Comparison of

different models for interpreting bone mineral density measure-
ments using DXA and MRI technology. Bone 1995;17:157-9.

[12] Leonard MB. A structural approach to skeletal fragility in

chronic kidney disease. Semin Nephrol 2009;29:133-43.

[28] Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.

Beneits of pamidronate in children with osteogenesis imper-
fecta: an open prospective study. Joint Bone Spine 2005;72:313-8. [13] Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight

development during four years of therapy with cyclical intrave-
nous pamidronate in children and adolescents with osteogen-
esis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-6.

[29] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G,

Travers R. Cyclic administration of pamidronate in chil-
dren with severe osteogenesis imperfecta. N Engl J Med
1998;339:947-52. [14] Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis

imperfecta types I, III, and IV: effect of pamidronate therapy
on bone and mineral metabolism. J Clin Endocrinol Metab
2003;88:986-92.

[30] Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J,

Travers R, et al. Pamidronate treatment of severe osteogenesis
imperfecta in children under 3 years of age. J Clin Endocrinol
Metab 2000;85:1846-50. [15] Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH. High

and low density in the same bone: a study on children and ado-
lescents with mild osteogenesis imperfecta. Bone 2005;37:634-41.

[31] Astrom E, Soderhall S. Beneicial effect of long term intravenous

bisphosphonate treatment of osteogenesis imperfecta. Arch Dis
Child 2002;86:356-64. [16] Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V,

et al. The volumetric bone density and cortical thickness in adult
patients affected by osteogenesis imperfecta. J Clin Densitom
2003;6:173-7.

[32] Allgrove J. Biphosphonates. Arch Dis Child 1997;76:73-5.

[33] Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intrave-

nous pamidronate on the bone tissue of children and adolescents
with osteogenesis imperfecta. J Clin Invest 2002;110:1293-9. [17] Rauch F, Lalic L, Roughley P, Glorieux FH. Genotype-

phenotype correlations in nonlethal osteogenesis imperfecta
caused by mutations in the helical domain of collagen type I.
Eur J Hum Genet 2010;18:642-7.

[34] Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphy-

seal lines in a child treated with pamidronate: histomorphomet-
ric analysis. J Bone Miner Res 2004;19:1191-3.

[18] Turner AG, Anderson PH, Morris HA. Vitamin D and bone

health. Scand J Clin Lab Invest Suppl 2012;243:65-72.

[35] Zacharin M, Bateman J. Pamidronate treatment of osteogenesis

imperfecta - lack of correlation between clinical severity, age at
onset of treatment, predicted collagen mutation and treatment
response. J Pediatr Endocrinol Metab 2002;15:163-74.

[19] Edouard T, Glorieux FH, Rauch F. Predictors and correlates of

vitamin D status in children and adolescents with osteogenesis
imperfecta. J Clin Endocrinol Metab 2011;96:3193-8. [36] Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D,

et al. Alendronate for the treatment of pediatric osteogen-
esis imperfecta: a randomized placebo-controlled study. J Clin
Endocrinol Metab 2011;96:355-64.

[20] Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and

density in children and adolescents with osteogenesis imper-
fecta: effect of intravenous pamidronate therapy. J Bone Miner
Res 2003;18:610-4. [37] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.

Risedronate in the treatment of mild pediatric osteogenesis
imperfecta: a randomized placebo-controlled study. J Bone Miner
Res 2009;24:1282-9.

[21] Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone

changes after pamidronate discontinuation in children and ado-
lescents with osteogenesis imperfecta. Bone 2007;40:821-7.

[22] Lowing K, Astrom E, Oscarsson KA, Soderhall S, Eliasson AC.

Effect of intravenous pamidronate therapy on everyday activi-
ties in children with osteogenesis imperfecta. Acta Paediatr
2007;96:1180-3.

[38] Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS. Effects of

short-term treatment with the bisphosphonates zoledronate and
pamidronate on rat bone: a comparative histomorphometric study
on the cancellous bone formed before, during, and after treatment.
Anat Rec 1997;249:458-68. [23] Choi JH, Shin YL, Yoo HW. Short-term eficacy of monthly

pamidronate infusion in patients with osteogenesis imperfecta.
J Korean Med Sci 2007;22:209-12.

[39] Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children

and adolescents with osteogenesis imperfecta: effect of treatment
discontinuation. J Clin Endocrinol Metab 2006;91:1268-74. [24] Bajpai A, Kabra M, Gupta N, Sharda S, Ghosh M. Intravenous

pamidronate therapy in osteogenesis imperfecta: response to
treatment and factors inluencing outcome. J Pediatr Orthop
2007;27:225-7.

[40] Ward KA, Adams JE, Freemont TJ, Mughal MZ. Can bisphos-

phonate treatment be stopped in a growing child with skeletal
fragility? Osteoporos Int 2007;18:1137-40.

[25] Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F,

Eryilmaz SK, et al. Successful results of pamidronate treatment in